Trinity Biotech Appoints Commercial Head, Reports Improved Q4 EBITDA Amid Transformation Progress

summarizeSummary

Trinity Biotech announced a new commercial operations head and reported significant improvements in Q4 2025 Adjusted EBITDA and gross margins, demonstrating progress in its Comprehensive Transformation Plan amidst ongoing financial challenges.

check_boxKey Events

• New Commercial Leadership Appointed

  Jerry Lydon has been appointed Head of North America Commercial Operations, signaling a strategic focus on strengthening revenue quality and profitability.

• Significant Adjusted EBITDA Improvement

  Q4 2025 Adjusted EBITDA improved substantially from a negative $7.0 million in Q4 2024 to a negative $0.5 million, reflecting enhanced operational efficiency.

• Progress on Transformation Plan

  The company reported successful scaling of outsourced manufacturing for TrinScreen™ HIV and commenced Uni-Gold™ HIV manufacturing, with benefits expected from Q2 2026.

• Gross Margin Expansion

  Gross margin increased over 400 basis points to 35.2% in Q4 2025, driven by changes to the company's operating structure under its transformation plan.

auto_awesomeAnalysis

This filing provides crucial updates for Trinity Biotech, a company recently flagged with going concern doubts. The appointment of a new Head of North America Commercial Operations signals a renewed focus on revenue and profitability. Critically, the company reported a substantial improvement in Q4 2025 Adjusted EBITDA, narrowing losses from $7.0 million to $0.5 million, and an increase in gross margins. These financial improvements, alongside successful scaling of outsourced manufacturing under its Comprehensive Transformation Plan, indicate tangible progress in addressing its operational and financial challenges. Investors should monitor continued execution of the transformation plan and further progress towards sustainable profitability.